Abstract
Abstract Systemic lupus erythematosus is often complicated by a circulating anticoagulant, yet serious hemorrhage is rare in patients with this complication. It has also been observed that thrombotic complications may occur. The authors found definite evidence of a circulating anticoagulant in 8 of 11 patients with systemic lupus erythematosus; of these, 1 had significant bleeding, and 4 others, 1 of whom died, developed thrombotic complications. The occurrence of thrombosis in patients with circulating anticoagulants has not been previously reported. The inhibition of clotting appeared to be related to suppression of platelet function and could usually be bypassed in vitro by the addition of a soybean substitute for platelets (Inosithin). The tendency toward thrombosis was manifested by an increased generation of thromboplastin as measured by the thromboplastin generation test.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
